Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Results from a Systematic Review of Advanced-Stage Hodgkin Lymphoma Treatments and a Matching-Adjusted Indirect Treatment Comparison of A+AVD vs PET-Guided ABVD

Fjoralba Kristo, Alexa Molinari, Zhiyi Lan, Victoria Federico Paly, Ramsha Khan, Abbey Poirier, Christina Soeun Kwon, Hoora Moradian, Bipin N. Savani, Athanasios Zomas, Ajibade Ashaye

Blood (2024) 144 (Supplement 1): 7752.

https://doi.org/10.1182/blood-2024-201001

Published: 2024

Journal Articles

The Comparative Effectiveness of A+AVD vs PET-guided ABVD for the Management of Patients with Advanced Hodgkin Lymphoma: A Systematic Review and Matching-Adjusted Indirect Treatment Comparison

Fjoralba Kristo, Victoria Federico Paly, Katherine Fazioli, Conor McCloskey, Sunita Nair, Bipin N. Savani, Athanasios Zomas, Ajibade Ashaye

Blood (2023) 142 (Supplement 1): 1713.

https://doi.org/10.1182/blood-2023-174845

Published: 2023

Journal Articles

Effectiveness and Safety of Ixazomib-Based Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated Outside the Clinical Trial Setting Via an Early Access Program (EAP) in Europe: Second Interim Analysis of the 'Use Via Early Access to Ixazomib' (UVEA-IXA) Study

Heinz Ludwig, MD, Evangelos Terpos, MD PhD, María-Victoria Mateos, MD PhD, Mario Boccadoro, Bhuvan Kishore, Karthik Ramasamy, Sylvie Fernandez, Fabio Ferri, Nawal Bent-Ennakhil, Athanasios Zomas, François Gavini, Roman Hajek, MD

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-136519

Published: 2020

Journal Articles

Progression-Free Survival and Overall Survival Among a Patient Cohort of Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom

Martine Bagot, MD PhD, Timothy Illidge, MD PhD, Nicola Pimpinelli, MD, Mehul Dalal, PhD, Athanasios Zomas, Chalid Assaf, MD, Nathalie Waser, PhD, Zhouqin He, MSc, Tina Li, MPH, Robert Sambrook, MSc, Fabrizio Trinchese, Meredith Little, Nawal Bent-Ennakhil, Pablo L. Ortiz-Romero, MD PhD

Blood (2019) 134 (Supplement_1): 5879.

https://doi.org/10.1182/blood-2019-126246

Published: 2019

Journal Articles

Evolving Treatment Trends in Relapsed/Refractory Multiple Myeloma (RRMM) in Europe from 2016 to 2018: Analysis of a Multi-National Survey

Maximilian Merz, Isabelle Vande Broek, MD PhD, Manuel Pérez, Dr., Brigitte Kolb, MD, Argiris Symeonidis, MD PhD, Emmanouil Nikolousis, Athanasios Zomas, Francisco Gonzalez, Lenka Kellermann, BS, MBA, Hartmut Goldschmidt

Blood (2019) 134 (Supplement_1): 3115.

https://doi.org/10.1182/blood-2019-122706

Published: 2019

Journal Articles

Evaluation of the Revised International Staging System (R-ISS) in an Independent Cohort of Unselected Patients with Multiple Myeloma

Efstathios Kastritis, MD, Evangelos Terpos, Maria Gavriatopoulou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Dimitrios Ziogas, Ioannis Panagiotidis, Despoina Fotiou, Dimitra Gika, Despoina Kalapanida, Eftychia Kafantari, Maria Roussou, Flora Zagouri, Stavroula Giannouli, Athanasios Zomas, Kostas Konstantopoulos, Meletios A. Dimopoulos

Blood (2015) 126 (23): 3045.

https://doi.org/10.1182/blood.V126.23.3045.3045

Published: 2015

Journal Articles

Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients

Blood (2014) 124 (21): 2113.

https://doi.org/10.1182/blood.V124.21.2113.2113

Published: 2014

Journal Articles

Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy

Meletios A. Dimopoulos, Evangelos Terpos, Maria Gavriatopoulou, Despoina Kalapanida, Evangelos Eleutherakis-Papaiakovou, Maria Roussou, Despoina Mparmparoussi, Athanasios Zomas, Dimitra Gika, Zafiris Kartasis, Charis Matsouka, Evangelos Kostis, Sofoklis Kontogiannis, Kostas Konstantopoulos, Efstathios Kastritis, MD

Blood (2014) 124 (21): 4738.

https://doi.org/10.1182/blood.V124.21.4738.4738

Published: 2014

Journal Articles

Frequency and Prognostic Significance of Hypercalcemia in Patients with Multiple Myeloma: An Analysis of the Database of the Greek Myeloma Study Group

Efstathios Kastritis, Eirini Katodritou, Anastasia Pouli, Eleftheria Hatzimichael, Sosana Delimpasi, Eurydiki Michalis, Athanasios Zomas, Zafiris Kartasis, Agapi Parcharidou, Dimitra Gika, Panagiotis Repousis, Ekaterini Stefanoudaki, Argiris Symeonidis, Panayiotis Panayiotidis, Konstantinos Konstantopoulos, Evangelos Terpos, Meletios Athanasios Dimopoulos, MD

Blood (2011) 118 (21): 5083.

https://doi.org/10.1182/blood.V118.21.5083.5083

Published: 2011

Journal Articles

No Significant Improvement In the Outcome of Patients with Waldenström's Macroglobulinemia Treated Over the Last 25 Years

Blood (2010) 116 (21): 3032.

https://doi.org/10.1182/blood.V116.21.3032.3032

Published: 2010

Journal Articles

The International Scoring System (ISS) for Multiple Myeloma Remains a Robust Prognostic Tool Independently of Patients' Renal Function

Blood (2010) 116 (21): 3036.

https://doi.org/10.1182/blood.V116.21.3036.3036

Published: 2010

Journal Articles

High Serum Lactate Dehydrogenase (LDH) Is An Important Prognostic Factor in the Era of Novel Agents and Adds to the Prognostic Value of the International Staging System (ISS) in Patients with Multiple Myeloma.

Dimopoulos A. Dimopoulos, Maria Roussou, Anastasia Pouli, Eirini Katodritou, Argiris Symeonidis, Eurydiki Michalis, Vassiliki Grigoraki, Nikolaos Anagnostopoulos, Athanasios Zomas, Sosana Delimpasi, Agapi Parharidou, Zafiris Kartasis, Nora-Athina Viniou, Dimitra Gika, Evangelos Terpos, Theofanis Economopoulos, Konstantinos Zervas

Blood (2009) 114 (22): 1819.

https://doi.org/10.1182/blood.V114.22.1819.1819

Published: 2009

Journal Articles

Improved Survival of Patients with Multiple Myeloma after the Introduction of Novel Agents and the Applicability of the International Staging System (ISS) An Analysis of the Greek Myeloma Study Group (GMSG)

Efstathios Kastritis, Konstantinos Zervas, Argiris Symeonidis, Evangelos Terpos, Sossana Delimpassi, Nicolaos Anagnostopoulos, Evridiki Michali, Athanasios Zomas, Irini Katodritou, Dimitra Gika, Anastasia Pouli, Dimitrios Christoulas, Maria Roussou, Theofanis Economopoulos, Meletios A Dimopoulos

Blood (2008) 112 (11): 655.

https://doi.org/10.1182/blood.V112.11.655.655

Published: 2008

Journal Articles

Mitoxantrone and Cytarabine Combination in Untreated Elderly Patients with Acute Myeloid Leukemia (AML): A Retrospective Single-Centre Analysis.

Theodore Marinakis, Vasilios Xanthopoulos, Athanasios Galanopoulos, Evrydiki Michalis, George Gortzolidis, Athanasios Zomas, Ioannis Tsourveloudis, Ioanna Savvidou, Myrsini Pergaminou, Antonios Angelidis, Ioanna Michail, Helen Goumakou, Elpiniki Griva, Alexandra Tsakri, Maria Georgiakaki, George Paterakis, Nikolaos I. Anagnostopoulos

Blood (2007) 110 (11): 4372.

https://doi.org/10.1182/blood.V110.11.4372.4372

Published: 2007

Journal Articles

Primary Treatment of Waldenstrom’s Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide.

Meletios A. Dimopoulos, MD, Athanasios Anagnostopoulos, M.D., Marie Christine Kyrtsonis, M.D., Constantinos Tsatalas, M.D., Garyfallia Kokkini, M.D., Panagiotis Repoussis, M.D., Athanasios Zomas, M.D., Argiris Symeonidis, M.D., Evridiki Michali, M.D., Nikolaos Anagnostopoulos, M.D., Evangelos Terpos, M.D., Theophanis Economopoulos, M.D., Gerasimos Pangalis, M.D.

Blood (2006) 108 (11): 128.

https://doi.org/10.1182/blood.V108.11.128.128

Published: 2006

Journal Articles

Predictive Factors for Response and Progression after Treatment with Rituximab in Previously Untreated Patients with Waldenstrom’s Macroglobulinemia (WM).

Athanasios Anagnostopoulos, MD, Steven P. Treon, MD, Konstantinos Zervas, MD, Andrew Branagan, MD, Dimitra Gika, Athanasios Zomas, MD, Marie Christine Kyrtsonis, MD, Amalia Vassou, MD, Nikolaos Anagnostopoulos, MD, Gerasimos Pangalis, MD, Meletios A. Dimopoulos, MD

Blood (2005) 106 (11): 3485.

https://doi.org/10.1182/blood.V106.11.3485.3485

Published: 2005

Journal Articles

Prognostic Value of Serum β2-Microglobulin in Patients with Waldenstrom’s Macroglobulinemia Requiring Treatment.

Athanasios Anagnostopoulos, MD, Konstantinos Zervas, MD, Evangelos Terpos, MD, Marie Christine Kyrtsonis, MD, Argyris Symeonidis, MD, Dimitra Gika, Konstantinos Bourantas, MD, Athanasios Zomas, MD, Nikolaos Angnostopoulos, MD, Gerasimos Pangalis, MD, Meletios A. Dimopoulos, MD

Blood (2005) 106 (11): 3415.

https://doi.org/10.1182/blood.V106.11.3415.3415

Published: 2005

Journal Articles

The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Treatment for Relapsed/Refractory Myeloma: Results of a Phase II Clinical Trial.

Evangelos Terpos, MD, PhD, Athanasios Anagnostopoulos, MD, PhD, Efstathios Kastritis, MD, Athanasios Zomas, MD, Christos Poziopoulos, MD, Nikolaos Anagnostopoulos, MD, PhD, Konstantinos Tsionos, MD, Meletios A. Dimopoulos, MD, PhD

Blood (2005) 106 (11): 363.

https://doi.org/10.1182/blood.V106.11.363.363

Published: 2005

Journal Articles

Deletion of Tumor Suppressor Genes (TSGS) in Patients with Myelodysplastic Syndrome (MDS).

Athanasios G. Galanopoulos, MD, PhD, Stephanos Papadhimitriou, MD, Ioannis Tsourveloudis, MD, Evridiki Michalis, MD, Theodoros Marinakis, MD, PhD, Anastasia Tsakiridou, MD, Ioanna Savvidou, MD, Vasilios Xanthopoulos, MD, George Theodoropoulos, MD, George Gortzolidis, MD, Athanasios Zomas, MD, Maria Georgiakaki, MD, Nikolaos I. Anagnostopoulos, MD, PhD

Blood (2005) 106 (11): 4907.

https://doi.org/10.1182/blood.V106.11.4907.4907

Published: 2005

Journal Articles

A Phase III Clinical Study of Treatment of Patients with Chronic Lymphoproliferative Disorders (CLPD) with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Combination.

Athanasios G. Galanopoulos, MD, PhD, Anastasia Tsakiridou, MD, Eurydiki Michalis, MD, Theodoros Marinakis, MD, George Gortzolidis, MD, Athanasios Zomas, MD, Vasilios Xanthopoulos, MD, Ioanna Savvidou, MD, George Theodoropoulos, MD, Vasiliki Grigoraki, MD, Nikolaos I. Anagnostopoulos, MD, PhD

Blood (2005) 106 (11): 4740.

https://doi.org/10.1182/blood.V106.11.4740.4740

Published: 2005

NARROW

Results from a Systematic Review of Advanced-Stage Hodgkin Lymphoma Treatments and a Matching-Adjusted Indirect Treatment Comparison of A+AVD vs PET-Guided ABVD

The Comparative Effectiveness of A+AVD vs PET-guided ABVD for the Management of Patients with Advanced Hodgkin Lymphoma: A Systematic Review and Matching-Adjusted Indirect Treatment Comparison

Effectiveness and Safety of Ixazomib-Based Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated Outside the Clinical Trial Setting Via an Early Access Program (EAP) in Europe: Second Interim Analysis of the 'Use Via Early Access to Ixazomib' (UVEA-IXA) Study

Progression-Free Survival and Overall Survival Among a Patient Cohort of Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom

Evolving Treatment Trends in Relapsed/Refractory Multiple Myeloma (RRMM) in Europe from 2016 to 2018: Analysis of a Multi-National Survey

Evaluation of the Revised International Staging System (R-ISS) in an Independent Cohort of Unselected Patients with Multiple Myeloma

Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients

Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy

Frequency and Prognostic Significance of Hypercalcemia in Patients with Multiple Myeloma: An Analysis of the Database of the Greek Myeloma Study Group

No Significant Improvement In the Outcome of Patients with Waldenström's Macroglobulinemia Treated Over the Last 25 Years

The International Scoring System (ISS) for Multiple Myeloma Remains a Robust Prognostic Tool Independently of Patients' Renal Function

High Serum Lactate Dehydrogenase (LDH) Is An Important Prognostic Factor in the Era of Novel Agents and Adds to the Prognostic Value of the International Staging System (ISS) in Patients with Multiple Myeloma.

Improved Survival of Patients with Multiple Myeloma after the Introduction of Novel Agents and the Applicability of the International Staging System (ISS) An Analysis of the Greek Myeloma Study Group (GMSG)

Mitoxantrone and Cytarabine Combination in Untreated Elderly Patients with Acute Myeloid Leukemia (AML): A Retrospective Single-Centre Analysis.

Primary Treatment of Waldenstrom’s Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide.

Predictive Factors for Response and Progression after Treatment with Rituximab in Previously Untreated Patients with Waldenstrom’s Macroglobulinemia (WM).

Prognostic Value of Serum β2-Microglobulin in Patients with Waldenstrom’s Macroglobulinemia Requiring Treatment.

The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Treatment for Relapsed/Refractory Myeloma: Results of a Phase II Clinical Trial.

Deletion of Tumor Suppressor Genes (TSGS) in Patients with Myelodysplastic Syndrome (MDS).

A Phase III Clinical Study of Treatment of Patients with Chronic Lymphoproliferative Disorders (CLPD) with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Combination.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only